Position of the Transparency Council – Attentin (dextroamphetamine)
At its meeting on 7 January 2025, the Transparency Council adopted position No. 4/2025 on the appropriateness of issuing approvals for reimbursement of the medicinal product Attentin (dextroamphetamine) for the indication: attention deficit hyperactivity disorder (ADHD)